ADC Therapeutics SA 8-K

What Happened
ADC Therapeutics SA filed a Form 8‑K on January 8, 2026, announcing a press release with preliminary, unaudited estimates for revenue for the quarter and year ended December 31, 2025, and a preliminary amount for cash and cash equivalents as of December 31, 2025. Management states these figures are estimates based on subjective judgments and have not been finalized or audited.

Key Details

• Date of disclosure: January 8, 2026.
• Items disclosed: preliminary revenue estimates for the quarter and full year ended Dec 31, 2025, and preliminary cash and cash equivalents as of Dec 31, 2025.
• Status of figures: preliminary, unaudited, based on management estimates and subject to change; not a comprehensive financial statement.
• The press release is included as Exhibit 99.1 to the 8‑K.

Why It Matters
Preliminary revenue and cash figures give investors an early view of ADC Therapeutics’ recent operating performance and liquidity heading into 2026, which can affect market expectations for quarterly results and funding needs. However, the company cautions these numbers are unaudited and may materially change when final results are prepared and reviewed, so investors should not place undue reliance on the preliminary figures.